These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 36091829)

  • 1. Recent advances of IDH1 mutant inhibitor in cancer therapy.
    Tian W; Zhang W; Wang Y; Jin R; Wang Y; Guo H; Tang Y; Yao X
    Front Pharmacol; 2022; 13():982424. PubMed ID: 36091829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
    Ma R; Yun CH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
    Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
    Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.
    Liu X; Gong Y
    Biomark Res; 2019; 7():22. PubMed ID: 31660152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence.
    Stemer G; Rowe JM; Ofran Y
    Blood Lymphat Cancer; 2021; 11():41-54. PubMed ID: 34188585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
    Bhavya B; Anand CR; Madhusoodanan UK; Rajalakshmi P; Krishnakumar K; Easwer HV; Deepti AN; Gopala S
    Cell Mol Neurobiol; 2020 Jan; 40(1):53-63. PubMed ID: 31485826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
    Ma T; Zou F; Pusch S; Xu Y; von Deimling A; Zha X
    J Med Chem; 2018 Oct; 61(20):8981-9003. PubMed ID: 29847930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.
    Thomas D; Wu M; Nakauchi Y; Zheng M; Thompson-Peach CAL; Lim K; Landberg N; Köhnke T; Robinson N; Kaur S; Kutyna M; Stafford M; Hiwase D; Reinisch A; Peltz G; Majeti R
    Cancer Discov; 2023 Feb; 13(2):496-515. PubMed ID: 36355448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
    Nassereddine S; Lap CJ; Haroun F; Tabbara I
    Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
    Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
    J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
    Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
    Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness.
    Liu ACH; Cathelin S; Yang Y; Dai DL; Ayyathan DM; Hosseini M; Minden MD; Tierens A; Chan SM
    Cancer Res; 2022 Dec; 82(23):4325-4339. PubMed ID: 36150062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
    Choe S; Wang H; DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Watts JM; Pollyea DA; Fathi AT; Tallman MS; Kantarjian HM; Stone RM; Quek L; Konteatis Z; Dang L; Nicolay B; Nejad P; Liu G; Zhang V; Liu H; Goldwasser M; Liu W; Marks K; Bowden C; Biller SA; Attar EC; Wu B
    Blood Adv; 2020 May; 4(9):1894-1905. PubMed ID: 32380538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.
    Kowalczyk A; Zarychta J; Lejman M; Latoch E; Zawitkowska J
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting isocitrate dehydrogenase (IDH) in cancer.
    Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
    Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consequences of
    Kaminska B; Czapski B; Guzik R; Król SK; Gielniewski B
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30857299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia.
    Cerchione C; Romano A; Daver N; DiNardo C; Jabbour EJ; Konopleva M; Ravandi-Kashani F; Kadia T; Martelli MP; Isidori A; Martinelli G; Kantarjian H
    Front Oncol; 2021; 11():639387. PubMed ID: 33898313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.